PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
238.00 - 242.07
140.53 - 242.25
26.77M / 38.44M (Avg.)
25.64 | 9.39
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
16.09%
Revenue growth at 50-75% of META's 25.65%. Martin Whitman would worry about competitiveness or product relevance.
12.01%
Gross profit growth under 50% of META's 28.85%. Michael Burry would be concerned about a severe competitive disadvantage.
15.12%
EBIT growth below 50% of META's 46.52%. Michael Burry would suspect deeper competitive or cost structure issues.
15.12%
Operating income growth under 50% of META's 46.52%. Michael Burry would be concerned about deeper cost or sales issues.
5.37%
Net income growth under 50% of META's 35.88%. Michael Burry would suspect the firm is falling well behind a key competitor.
5.41%
EPS growth under 50% of META's 49.40%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
5.56%
Diluted EPS growth under 50% of META's 47.56%. Michael Burry would worry about an eroding competitive position or excessive dilution.
0.33%
Share count expansion well above META's 0.25%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
0.25%
Diluted share count expanding well above META's 0.24%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-4.39%
Negative OCF growth while META is at 37.82%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-13.11%
Negative FCF growth while META is at 47.50%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
610.45%
10Y revenue/share CAGR 1.25-1.5x META's 552.73%. Bruce Berkowitz would investigate brand strength or geographical expansion fueling growth.
131.47%
5Y revenue/share CAGR under 50% of META's 552.73%. Michael Burry would suspect a significant competitive gap or product weakness.
50.07%
3Y revenue/share CAGR under 50% of META's 195.74%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
803.01%
10Y OCF/share CAGR 1.25-1.5x META's 710.12%. Bruce Berkowitz would confirm if the firm's long-term capital allocation yields better cash returns.
125.45%
Below 50% of META's 710.12%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
74.43%
3Y OCF/share CAGR under 50% of META's 247.57%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
352.08%
Below 50% of META's 887.91%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
85.36%
Below 50% of META's 887.91%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
53.33%
Below 50% of META's 494.15%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
612.93%
10Y equity/share CAGR at 50-75% of META's 912.61%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
124.74%
Below 50% of META's 912.61%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
54.57%
Below 50% of META's 232.07%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
14.82%
AR growth is negative/stable vs. META's 30.07%, indicating tighter credit discipline. David Dodd confirms it doesn't hamper actual sales.
-52.06%
Inventory is declining while META stands at 0.00%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
4.72%
Asset growth at 50-75% of META's 8.86%. Martin Whitman questions if the firm is lagging expansions or if the competitor invests more aggressively.
3.34%
Under 50% of META's 9.11%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
-0.08%
We’re deleveraging while META stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
0.72%
R&D dropping or stable vs. META's 1.56%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
17.16%
SG&A growth well above META's 19.81%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.